NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer
File(s)1-s2.0-S2372770520300218-main.pdf (3.06 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Oncolytic viruses (OVs) can trigger profound innate and adaptive immune responses, which have the potential both to potentiate and reduce the activity of OVs. Natural killer (NK) cells can mediate potent anti-viral and anti-tumoral responses, but there are no data on the role of NK cells in oncolytic adenovirus activity. Here, we have used two different oncolytic adenoviruses—the Ad5 E1A CR2-deletion mutant dl922-947 (group C) and the chimeric Ad3/Ad11p mutant enadenotucirev (group B)—to investigate the effect of NK cells on overall anti-cancer efficacy in ovarian cancer. Because human adenoviruses do not replicate in murine cells, we utilized primary human NK cells from peripheral blood and ovarian cancer ascites. Our results show that dl922-947 and enadenotucirev do not infect NK cells, but induce contact-dependent activation and anti-cancer cytotoxicity against adenovirus-infected ovarian cancer cells. Moreover, manipulation of NK receptors DNAM-1 (DNAX accessory molecule-1) and TIGIT (T cell immunoreceptor with Ig and ITIM domains) significantly influences NK cytotoxicity against adenovirus-infected cells. Together, these results indicate that NK cells act to increase the activity of oncolytic adenovirus in ovarian cancer and suggest that strategies to augment NK activity further via the blockade of inhibitory NK receptor TIGIT could enhance therapeutic potential of OVs.
Date Issued
2020-03-27
Date Acceptance
2020-02-10
Citation
Molecular Therapy - Oncolytics, 2020, 16, pp.289-301
ISSN
2372-7705
Publisher
Elsevier (Cell Press)
Start Page
289
End Page
301
Journal / Book Title
Molecular Therapy - Oncolytics
Volume
16
Copyright Statement
©2020 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Cancer Research UK
Ovarian Cancer Action
Grant Number
RDB01
RDB01
RG71079
n/a
Subjects
Adenovirus
DNAM-1
NK cell
Oncolytic virus
Ovarian cancer
TIGIT
Publication Status
Published
Date Publish Online
2020-02-15